Diosmin + Hesperidin (Daflon® 1000). For the Relief and Prevention of Hemorrhoidal disease.

How does Diosmin + Hesperidin (Daflon® 1000) work?

wave icon

Diosmin + Hesperidin (Daflon® 1000) is a convenient oral venoactive treatment that gets to the root of hemorrhoid problems by working to treat the veins that become dilated and inflamed during a hemorrhoidal episode. 1

Diosmin + Hesperidin (Daflon® 1000) quickly works to treat hemorrhoidal disease by reducing the associated signs and symptoms of the disease and can also strengthen the overall tone of your veins, helping to improve blood flow and reducing venous congestion for long term management of hemorrhoids. 1

Formulated for Fast Absorption and Relief

wave icon

Diosmin + Hesperidin (Daflon® 1000) is a clinically proven, effective and discrete oral treatment derived from natural ingredients and specially formulated for maximum absorption. 1

This improved absorption means Diosmin + Hesperidin (Daflon® 1000) can rapidly get to the root of the problem to conveniently and discretely reduce the duration, intensity and recurrence of hemorrhoid episodes, with different dosing options for fast-acting treatment of acute episodes, or ongoing maintenance for recurring hemorrhoid disease. 2

Rapid Relief

wave icon

Diosmin + Hesperidin (Daflon® 1000) is clinically proven to quickly and effectively treat hemorrhoidal episodes for rapid relief. 1,2 In just two days, 42% of users demonstrated a reduction in their symptoms and in only three days, 80% reported that their bleeding had stopped. After a single week, most people reported that their symptoms, including bleeding, pain and discharge had resolved.

Diosmin + Hesperidin (Daflon® 1000) can also be used for up to two months to treat chronic and recurring hemorrhoids. With just one pill a day, 71% of users reported fewer instances of acute episodes. 5

Rapid relief for Acute Hemorrhoids

At 2 days

42% of patients experienced mild reduction of symptoms

At 3 days

80% of patients' bleeding stopped 2

At 7 days

94% of patients' bleeding stopped 2 84% of patients' pain stopped 4 81% of patients' discharge stopped 4

Ongoing treatment for Recurrent Hemorrhoids

At 2 months

31% Less severe symptoms

43% Shorter duration of symptoms

71% fewer recurences

Naturally sourced, scientifically prepared.

wave icon

The active ingredient in Diosmin + Hesperidin (Daflon® 1000) is a micronized purified flavonoid fraction (MPFF) 6 containing 90% diosmin and 10% other flavonoids expressed as hesperidin.

Diosmin + Hesperidin (Daflon® 1000)’s flavonoids are extracted from immature oranges that are rich in these naturally occurring plant chemicals. The compounds undergo a process of purification and refinement where the particles are made to collide with each other at high speeds (micronization), reducing them to tiny particles, less than 2 μm in size (micronized). These smaller particles are absorbed twice as easily by the body and are a key ingredient of Diosmin + Hesperidin (Daflon® 1000)’s success as a treatment for improving vein health and tone in Chronic Venous Insufficiency and Hemorrhoids. 6

Safety Information:

Diosmin + Hesperidin (Daflon® 1000)

COMPOSITION: Micronized, purified flavonoid fraction 1000 mg: 900 mg diosmin; 100 mg flavonoids expressed as hesperidin.

INDICATIONS: Treatment of organic and idiopathic chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs; pain; nocturnal cramps. Treatment of hemorrhoids and acute hemorrhoidal attacks. 

DOSAGE AND ADMINISTRATION: In venous disease: 1000 mg daily. In acute hemorrhoidal attacks: 3000 mg per day for the first 4 days, then 2000 mg per day for 3 days. Method of administration: Oral route.

CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients. 

WARNINGS: The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions. The treatment must be short-term. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed. Excipients: sodium-free.

INTERACTION: None. 

PREGNANCY/LACTATION: Treatment should be avoided. 

UNDESIRABLE EFFECTS: Common: diarrhea, dyspepsia, nausea, vomiting. Uncommon: colitis. Rare: dizziness, headache, malaise, rash, pruritus, urticaria. Frequency not known: abdominal pain, isolated face, lip, eyelid edema. Exceptionally, Quincke’s edema. 

PROPERTIES: Vascular protector and venotonic. Daflon acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance. 

PRESENTATION: Pack of 30 film-coated tablets. 

STORAGE: Store at temperatures not exceeding 30°C.

For suspected adverse drug reaction, report to the FDA at www.fda.gov.ph. 

SERVIER PHILIPPINES, INC. Unit AD, 11th Floor, 8 Rockwell, Hidalgo Drive, Rockwell Center, Makati City, 1210. ​

Further information available upon request.

Diosmin + Hesperidin (Daflon® 500)

COMPOSITION: Micronized, purified flavonoid fraction 500 mg: 450 mg diosmin; 50 mg flavonoids expressed as hesperidin. 

INDICATIONS: Treatment of organic and idiopathic chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs; pain; nocturnal cramps. Treatment of hemorrhoids and acute hemorrhoidal attacks. 

DOSAGE AND ADMINISTRATION: In venous disease: 1000 mg daily. In acute hemorrhoidal attacks: 3000 mg per day for the first 4 days, then 2000 mg per day for 3 days. Method of administration: Oral route.

CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients. 

WARNINGS: The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions. The treatment must be short-term. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed. Excipients: sodium-free.

INTERACTION: None. 

PREGNANCY/LACTATION: Treatment should be avoided. 

UNDESIRABLE EFFECTS: Common: diarrhea, dyspepsia, nausea, vomiting. Uncommon: colitis. Rare: dizziness, headache, malaise, rash, pruritus, urticaria. Frequency not known: abdominal pain, isolated face, lip, eyelid edema. Exceptionally, Quincke’s edema. 

PROPERTIES: Vascular protector and venotonic. Daflon acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance. 

PRESENTATION: Pack of 30 film-coated tablets. 

STORAGE: Store at temperatures not exceeding 30°C.

For suspected adverse drug reaction, report to the FDA at www.fda.gov.ph.

SERVIER PHILIPPINES, INC. Unit AD, 11th Floor, 8 Rockwell, Hidalgo Drive, Rockwell Center, Makati City, 1210.

Further information available upon request.

References:

  1. Shelygin Y, Krivokapic Z, Frolov SA, et al. Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease. Curr Med Res Opin. 2016;32(11):1821-1826.
  2. Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding due to acute internal hemorrhoids. Br J Surg. 2000;87:868-872.
  3. Garner RC, Garner JV, Gregory S, Whattam M, Calam A, Leong D. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J Pharm Sci. 2002;91:32-40.
  4. Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology. 1994;45:566-573.
  5. Godeberge P. Daflon 500mg is significantly more effective than placebo in the treatment of hemorrhoids. Phlebology. 1992;7(suppl 2):61-63.
  6. Summary of Product Characteristics Daflon 7. Greenspon. Thrombosed external hemorrhoids: outcome after conservative or surgical treatment J.Dis Colon Rectum 2004. 47(9):1493-8.

2024